Dr. Berrino Discusses Medications on Guess Who’s Coming to Dinner

Italy’s public broadcaster Rai has reignited debate over the safety and marketing of weight-loss drugs following a segment on its long-running program Indovina chi viene a cena, which examined the risks of medications marketed as “disguised” diabetes treatments while carrying dangerous side effects. The May 12, 2026 broadcast, featuring oncologist and epidemiologist Dr. Franco Berrino, highlighted how such drugs—often promoted as miracle solutions—have led to severe health consequences abroad while evading scrutiny in Italy.

The episode underscored a broader contradiction in Italian health trends: while the Mediterranean diet, celebrated for its longevity benefits among centenarians in regions like Cilento, remains a global model, childhood obesity rates in Campania have reached alarming levels. According to the program, children in the region now rank as the most overweight in Italy, reversing the positive trends observed in elderly populations. Dr. Berrino, a frequent contributor to the show, linked this paradox to the growing reliance on pharmaceutical interventions over sustainable lifestyle changes.

“The only effective way to lose weight without risking serious side effects is through a healthy lifestyle,” the program cited Berrino as stating, echoing a stance he has repeatedly advocated in media appearances. The segment also drew attention to a 2025 investigation into a weight-loss drug marketed as an antidiabetic, which caused fatalities overseas but reportedly faced cover-ups in Italy. Rai’s report did not name the specific drug but framed the issue as part of a wider pattern of unregulated marketing tactics targeting vulnerable populations.

While the program did not provide new data on the drug’s prevalence in Italy, it amplified concerns already raised by consumer advocacy groups and medical professionals. Earlier this year, the Italian Society of Endocrinology warned against the misuse of glucose-lowering medications for weight loss, citing cases of cardiovascular complications and pancreatic damage. The Rai segment further complicated the narrative by juxtaposing the success of the Mediterranean diet—long associated with reduced obesity and extended lifespan—against the rising tide of processed foods and pharmaceutical dependence among younger Italians.

Dr. Berrino’s involvement in the discussion is notable given his decades-long research on nutrition and longevity. His work, including studies on centenarians in Cilento, has consistently emphasized the superiority of dietary and exercise-based approaches over quick-fix medications. The Indovina chi viene a cena episode, however, did not include specific statistics on drug-related incidents in Italy, focusing instead on the broader cultural and regulatory failures enabling their proliferation.

Public health experts have long cautioned against the “medicalization” of weight loss, arguing that the pharmaceutical industry’s aggressive marketing—often leveraging loopholes in drug classification—distracts from systemic solutions. In Italy, where obesity rates have risen steadily over the past decade, the debate now centers on whether stricter oversight of weight-loss medications is feasible amid a backdrop of economic pressures and dietary habits shifting toward convenience foods.

The Rai program’s timing is significant, coming as global regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), face mounting scrutiny over their approval processes for novel weight-loss drugs. While Italy has not yet faced major legal challenges related to such medications, the episode suggests growing domestic pressure for transparency—particularly as international cases of harm from misbranded drugs continue to surface.

For now, the conversation remains focused on education and policy. Dr. Berrino’s message—reiterated in the broadcast—stresses that longevity is not a product of pills but of consistent, evidence-based habits. Yet, with childhood obesity rates climbing and pharmaceutical interventions increasingly normalized, the challenge for Italian authorities lies in reversing a trend that threatens to undermine one of the country’s most celebrated public health achievements.

No further details on specific regulatory actions or pending investigations were provided in the Rai segment. The program’s producers did not respond to requests for additional data on the drug in question or the scope of its distribution in Italy.